Skip to main content

Table 1 Clinical, molecular and biochemical characterization of 15 new EDS VIA patients.

From: Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation

 

P1

P2

P3

P4a

P4b

P5

P6

P7a

P7b

P7c

P8

P9

P10

P11

P12

Sex

M

M

F

M

M

M

F

F

F

M

M

M

F

F

F

Age at diagnosis

9 m

27 y

14 y

4 y

6 m

9 y

5 m

15 m

14 m

13 m

19 m

16 y

16 y

18 m

8 m

Ethnicity

Mazedonia

Serbia

Iran

Turkey

Turkey

Turkey

Netherland

Somalia

Somalia

Somalia

Turkey

Turkey

Spain

Turkey

Iraqui

Consanguinity

+

-

+

+

+

+

-

+

+

+

+

+

+

+

+

Urinary LP/HP #

8.16

5.47

5.59

4.02

9.5

5.15

8.48

8.32

9.03

not done

6.98

6.1

6.51

6.6

7.8

PLOD1 mutation

Dup/Dup

p.L85P/p.L85P *

c.1471-1 G > A/

c.1471-1 G > A*

Dup/Dup

Dup/Dup

c.1095C > T/

c.1095C > T*

c.1651-2 A > G/

c.1651-2 A > G*

p.G678R/p.G678R

p.G678R/

p.G678R

p.G678R/

p.G678R

DNA not available

p.Q345X/

p.Q345X*

c.466+ 1G > A/

c.466+ 1G > A*

DNA not available

p.Trp419leufsX48*/

p.Trp419leufsX48*

muscular hypotonia at birth

+

-

+

+

+

+

+

+

+

+

+

+

+

+

+

Kyphoscoliosis at birth

+

-

+

+

+

+

+

+

-

-

+

+

-

+

+

Marfanoid habitus

+

+

+

+

+

+

+

+

+

-

-

+

-

-

+

Delayed gross motor development

+

-

+

+

+

+

+

+

+

+

+

+

+

+

+

delayed cognitive development

-

-

-

-

-

-

-

-

-

-

+

+

+

+

+

Rupture of artery

-

+

-

-

-

-

-

-

-

-

-

-

-

-

+

Smooth velvety skin

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

Extensibel fragile skin

-

-

+

?

?

+

+

?

+

+

+

?

+

?

+

Joint laxity

+

+

+

+

+

+

?

+

+

+

+

+

+

+

+

Hip dislocation at birth

+

-

+

-

-

+

-

-

-

-

+

-

-

-

+

Neuromuscular workup

+

-

-

-

-

+

-

+

-

-

+

-

+

+

-

Independent walking at age

2 y

1.5 y

4 y

?

?

?

2 y

n.a.

°

2 y

n.a

n.a

2 y

°

°

*newly described mutation

               
  1. +, Finding present; -, finding absent; ? no information available,; °, patient < 24 months at last exam; n.a, not able to; m, month and y, year and # LP/HP in normal control: 0.20 ± 0.05 (range 0.10-0.38); *, newly described mutation; §, common duplication of exon 10 to exon 16.